Navneet Natt's research while affiliated with Northern Ontario School of Medicine and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (9)
Background
Patients with inflammatory bowel disease (IBD) may require surgical intervention for management of their disease. There is a rising incidence of IBD in racial and ethnic minorities but studies regarding healthcare utilization patterns in these populations have yielded variable results.
Purpose
We aimed to examine the differences in surg...
Discrepancies in phase two and three studies can result in significant patient and financial burden, as well as the nonapproval of potentially efficacious drugs. We aimed to determine whether this discrepancy exists for clinical trials in inflammatory bowel disease (IBD). Electronic databases (MEDLINE and Embase) and clinical trial repositories wer...
Background
The incidence of inflammatory bowel disease (IBD) is rising worldwide though it remains unknown how race and ethnicity mediate health-care utilization. We aimed to better define this relationship in this systematic review and meta-analysis.
Methods
We explored the impact of race or ethnicity on the likelihood of needing an IBD-related s...
Background and aims:
While endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC), there is conflicting data on associated adverse events. The aims of this systematic review and meta-analysis are to (1) compare ERCP-related adverse events in patients with and with...
Background
Endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC). Although the complications of ERCP are well known in the general population, there is conflicting data regarding complications in patients with PSC. Factors that predict ERCP-related adverse events...
Background
There is increasing interest in direct oral anticoagulants (DOACs) given their safety and convenience in atrial fibrillation compared to vitamin K antagonists (VKAs). However, the use of DOACs in left ventricular (LV) thrombi is considered off-label, with current guidelines recommending VKAs. The aim of this meta-analysis was to compare...
Citations
... is abstract was previously published in the Journal of the Canadian Association of Gastroenterology [46]. e authors thank Ms. Sophie Regalado, Research and Scholarly Communications Librarian at NOSM University for her assistance with the search strategy. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/754119962791940-1556807618767_Q64/Sacha-Dubois.jpg)
... As non-vitamin K antagonist oral anticoagulants (NOACs) come with potentially practical advantages over warfarin, NOACs are increasingly used as off-label anticoagulant therapy in patients with intracardiac thrombi without the necessity for frequent laboratory monitoring. Compared with vitamin K antagonists (VKAs), NOACs were non-inferior in the efficacy and safety for the treatment of LV thrombus in two small randomized clinical trials (RCTs) [6,7] and several meta-analyses [8][9][10][11]. In decades of research, earlier guidelines on anticoagulation for LV thrombus primarily recommended the use of VKAs therapy for 3 months [5,12], while the latest American Heart Association scientific statement (2022) recommended that NOACs could be a reasonable alternative to warfarin in patients with LV thrombus, based on supportive though insufficiently powered randomized data [13]. ...
